SG11201606652PA - Solid forms of an ion channel modulator - Google Patents
Solid forms of an ion channel modulatorInfo
- Publication number
- SG11201606652PA SG11201606652PA SG11201606652PA SG11201606652PA SG11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA
- Authority
- SG
- Singapore
- Prior art keywords
- ion channel
- solid forms
- channel modulator
- modulator
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939640P | 2014-02-13 | 2014-02-13 | |
| PCT/US2015/015652 WO2015123434A1 (en) | 2014-02-13 | 2015-02-12 | Solid forms of an ion channel modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606652PA true SG11201606652PA (en) | 2016-09-29 |
Family
ID=52597268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606652PA SG11201606652PA (en) | 2014-02-13 | 2015-02-12 | Solid forms of an ion channel modulator |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9273038B2 (en) |
| EP (1) | EP3105227A1 (en) |
| JP (1) | JP2017505788A (en) |
| KR (1) | KR20160118358A (en) |
| CN (1) | CN105980380A (en) |
| AR (1) | AR102804A1 (en) |
| AU (1) | AU2015217129A1 (en) |
| BR (1) | BR112016018464A2 (en) |
| CA (1) | CA2881544A1 (en) |
| EA (1) | EA201691360A1 (en) |
| HK (1) | HK1226397A1 (en) |
| IL (1) | IL246959A0 (en) |
| MX (1) | MX2016010563A (en) |
| SG (1) | SG11201606652PA (en) |
| TW (1) | TW201613908A (en) |
| WO (1) | WO2015123434A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI510480B (en) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| NO3175985T3 (en) | 2011-07-01 | 2018-04-28 | ||
| TW201837023A (en) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | Fused heterocyclic compounds as ion channel modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| ZA200600197B (en) * | 2003-07-02 | 2007-06-27 | Vertex Pharma | Pyrimidines useful as modulators of voltage-gated ion channels |
| AU2010276537B2 (en) * | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| TW201837023A (en) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | Fused heterocyclic compounds as ion channel modulators |
| WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2015
- 2015-02-11 CA CA2881544A patent/CA2881544A1/en not_active Abandoned
- 2015-02-11 TW TW104104508A patent/TW201613908A/en unknown
- 2015-02-12 WO PCT/US2015/015652 patent/WO2015123434A1/en active Application Filing
- 2015-02-12 AR ARP150100430A patent/AR102804A1/en unknown
- 2015-02-12 EA EA201691360A patent/EA201691360A1/en unknown
- 2015-02-12 EP EP15707464.2A patent/EP3105227A1/en not_active Withdrawn
- 2015-02-12 KR KR1020167024842A patent/KR20160118358A/en not_active Application Discontinuation
- 2015-02-12 JP JP2016551186A patent/JP2017505788A/en active Pending
- 2015-02-12 US US14/620,970 patent/US9273038B2/en active Active
- 2015-02-12 MX MX2016010563A patent/MX2016010563A/en unknown
- 2015-02-12 BR BR112016018464A patent/BR112016018464A2/en not_active IP Right Cessation
- 2015-02-12 AU AU2015217129A patent/AU2015217129A1/en not_active Abandoned
- 2015-02-12 SG SG11201606652PA patent/SG11201606652PA/en unknown
- 2015-02-12 CN CN201580008148.2A patent/CN105980380A/en active Pending
-
2016
- 2016-07-26 IL IL246959A patent/IL246959A0/en unknown
- 2016-12-23 HK HK16114668A patent/HK1226397A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2881544A1 (en) | 2015-08-13 |
| US20150225383A1 (en) | 2015-08-13 |
| TW201613908A (en) | 2016-04-16 |
| AR102804A1 (en) | 2017-03-29 |
| CN105980380A (en) | 2016-09-28 |
| JP2017505788A (en) | 2017-02-23 |
| MX2016010563A (en) | 2016-12-12 |
| HK1226397A1 (en) | 2017-09-29 |
| EP3105227A1 (en) | 2016-12-21 |
| BR112016018464A2 (en) | 2017-08-08 |
| WO2015123434A1 (en) | 2015-08-20 |
| US9273038B2 (en) | 2016-03-01 |
| EA201691360A1 (en) | 2017-07-31 |
| AU2015217129A1 (en) | 2016-08-11 |
| IL246959A0 (en) | 2016-09-29 |
| KR20160118358A (en) | 2016-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283582A (en) | Modulators of ror-gamma | |
| HK1256599A1 (en) | Modulators of ror-gamma | |
| IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
| EP3183346A4 (en) | Channel modulators | |
| EP3800963C0 (en) | Clear channel assessment procedure at master devices | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| EP3127016A4 (en) | Provable geo-location | |
| SI3845221T1 (en) | Solid state forms of sofosbuvir | |
| GB201418182D0 (en) | Ion modification | |
| IL246979A0 (en) | Solid state forms of sofosbuvir | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| GB201604627D0 (en) | Improved method of FT-IMS | |
| GB201418395D0 (en) | Cyclo-depolymerisation of polybutadiene | |
| ZA201804342B (en) | Channel section | |
| HK1226397A1 (en) | Solid forms of an ion channel modulator | |
| EP3100230A4 (en) | Segments of contacts | |
| GB2535265B (en) | Ion source | |
| PL3111151T3 (en) | Method of operating an hydraulic-binder rotary-furnace | |
| SG11201600348XA (en) | Insulator target | |
| SG11201607445QA (en) | Methods of modulating wars2 | |
| HK1243457A1 (en) | Channel modulators | |
| PT3377106T (en) | Modulation of ciliogenesis | |
| IL250976A0 (en) | Broadcast channel testing | |
| IL249332A0 (en) | Solid state forms of sofosbuvir | |
| GB201418511D0 (en) | Ion source |